The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

EMA Accepts Teva's MAA for Subcutaneous Olanzapine LAI for Schizophrenia

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and Medincell announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. This investigational subcutaneous formulation, administered every four weeks, aims to address treatment adherence challenges and fill a significant unmet need for a viable long-acting olanzapine option in Europe. The submission is supported by an extensive clinical development program, including the Phase 3 SOLARIS study, which demonstrated efficacy and a systemic safety profile consistent with oral olanzapine.

• The EMA's acceptance of the MAA for TEV-‘749 marks a crucial step towards providing a novel long-acting injectable olanzapine option for adults with schizophrenia. This addresses a significant unmet medical need, as current treatment options have been limited by the lack of a practical, long-acting olanzapine formulation, despite daily oral olanzapine being a commonly prescribed antipsychotic.
• TEV-‘749 is designed as a subcutaneous formulation administered every four weeks, offering the proven efficacy and safety profile consistent with oral olanzapine. Its development program, including the pivotal Phase 3 SOLARIS study, supports its potential to improve treatment adherence and contribute to long-term disease management for individuals living with schizophrenia.
• The innovative treatment utilizes SteadyTeq™, a proprietary copolymer technology from Medincell, which enables the controlled, steady, and prolonged release of olanzapine. This technology is also behind UZEDY®, an FDA-approved treatment for schizophrenia distributed by Teva in the United States, highlighting its proven capability in long-acting injectable drug delivery.

Addressing Key Challenges in Schizophrenia Treatment Adherence

Current schizophrenia treatment faces significant challenges that limit therapeutic outcomes and patient quality of life. Despite decades of research and drug development, antipsychotic medications demonstrate only modest efficacy and are associated with substantial side effects and adherence problems. These limitations contribute to persistent disability and high healthcare costs for patients with this complex neuropsychiatric disorder.

• Limited efficacy against core symptoms - At least 20% of individuals with schizophrenia do not experience substantial response from antipsychotic monotherapy, and up to one-third of patients remain resistant to dopamine-blocking antipsychotics despite adequate treatment trials

• Inadequate treatment of negative and cognitive symptoms - While antipsychotics effectively reduce positive symptoms (hallucinations, delusions), they demonstrate minimal impact on negative symptoms (apathy, social withdrawal) and cognitive deficits, which are primary drivers of functional disability

• High rates of medication non-adherence - Poor adherence is pervasive, with studies showing 40% of patients having medication possession ratios below 0.8, particularly affecting younger patients, African-Americans, and those with unsteady income or acute illness phases

• Significant side effect burden - Antipsychotics cause troublesome adverse effects including extrapyramidal symptoms, metabolic disorders, weight gain, and cardiovascular risks, with older patients particularly vulnerable to movement disorders and metabolic syndrome

• Treatment-resistant disease prevalence - Approximately one-third of patients develop treatment-resistant schizophrenia, and even clozapine, the gold standard for resistant cases, fails in 40-70% of treatment-resistant patients

• Suboptimal long-term outcomes - Despite requiring lifelong medication, 70% of patients do not achieve complete recovery, and many experience persistent functional impairment affecting employment, social relationships, and independent living

• Implementation barriers in clinical practice - Psychiatrists often rely on intensive counseling rather than structured adherence interventions, with low implementation rates for systematic follow-up care and family psychoeducation programs

• Limited therapeutic innovation - The lack of success in discovering more effective pharmacotherapy has led to pharmaceutical industry disengagement from neuropsychiatry, hampering development of novel treatment mechanisms for this complex disorder

Understanding Olanzapine's Safety and Efficacy Profile

Published safety and tolerability data for olanzapine demonstrates a complex profile that varies across indications and patient populations. In schizophrenia, olanzapine shows comparable tolerability to other atypical antipsychotics regarding extrapyramidal symptoms, with lower incidence compared to traditional antipsychotics and reduced need for anti-Parkinsonian medications. Long-term studies reveal superior treatment persistence, with patients maintaining olanzapine therapy for significantly longer periods compared to other antipsychotics (median 30.0 months versus 23.1 months for risperidone). The drug demonstrates minimal prolactin elevation and favorable extrapyramidal symptom profiles, though approximately 75% of patients experience some adverse events including anticholinergic symptoms and sleep disturbances.

The most significant tolerability concern across all indications is metabolic dysfunction, particularly substantial weight gain and dyslipidemia. Clinical trials consistently demonstrate that olanzapine-treated patients experience greater weight gain compared to other atypical antipsychotics, with mean increases of 11.3 kg reported in bipolar disorder studies. This metabolic burden is particularly pronounced in pediatric populations, where olanzapine is associated with weight gain, dyslipidemia, and transaminase elevations, leading to recommendations for second-line positioning in youth. The rapid onset and magnitude of weight gain often necessitates early intervention decisions before substantial metabolic changes occur.

In specialized populations, tolerability profiles show indication-specific patterns. For bipolar disorder, olanzapine demonstrates similar safety to traditional mood stabilizers and first-generation antipsychotics, with no apparent compliance advantages. However, in elderly patients with dementia, olanzapine shows increased risks for falls (17.9% versus 6.9% with risperidone) and greater laxative requirements, despite using doses 50% lower than maximum recommended levels. The clinical utility of olanzapine reflects a therapeutic dilemma where effectiveness advantages must be weighed against metabolic risks, particularly in patients with low baseline risk for metabolic syndrome, requiring careful monitoring and individualized risk-benefit assessment.

TEV-‘749's Potential Impact on Schizophrenia Treatment

Recent clinical evidence reveals that investigational therapies for schizophrenia demonstrate mixed efficacy profiles when compared to established standard-of-care treatments. The most promising investigational agents include novel non-dopaminergic mechanisms such as xanomeline-trospium chloride (muscarinic agonist), which recently received FDA approval, and ulotaront (TAAR1 agonist), which showed a favorable safety profile at 100mg dosing with no significant dose-response relationship for all-cause dropout (RR=1.10, 95% CI: 0.57-2.12). However, several other investigational compounds including bitopertin (GlyT-1 inhibitor) and pimavanserin (5-HT2A antagonist) have had their clinical development programs halted despite early therapeutic promise. Metabotropic glutamate receptor modulators showed mixed results, with higher discontinuation rates due to adverse events (OR=1.43, 95% CI: 1.08-1.89) compared to standard treatments.

Comparative effectiveness studies continue to reinforce the superiority of clozapine as the gold standard for treatment-resistant schizophrenia, affecting approximately 30% of patients with the condition. A comprehensive 2013 Bayesian meta-analysis of 212 trials involving 43,049 participants demonstrated clozapine's highest efficacy among 15 antipsychotic agents (standardized mean difference 0.88, 95% CI: 0.73-1.03), followed by amisulpride (0.66) and olanzapine (0.59). Recent 2026 systematic reviews confirmed no significant differences in global clinical outcomes between clozapine and olanzapine, though clozapine exhibited distinct metabolic liabilities including notable triglyceride elevations and higher dropout rates due to adverse effects.

The therapeutic landscape demonstrates that while investigational therapies offer novel mechanisms of action, they have yet to demonstrate clear superiority over established second-generation antipsychotics in terms of efficacy endpoints. Standard treatments continue to show substantial efficacy advantages over placebo across all measured domains, with the FDA-approved olanzapine/samidorphan combination representing a notable advancement in mitigating metabolic side effects while preserving antipsychotic efficacy. The evidence suggests that future investigational therapies will need to demonstrate not only non-inferiority to current standards but also meaningful improvements in tolerability profiles or efficacy in treatment-resistant populations to establish clinical utility.

A New Long-Acting Olanzapine Option for European Schizophrenia Care

The European Medicines Agency's acceptance of the Marketing Authorization Application for Teva and Medincell's subcutaneous olanzapine long-acting injectable (TEV-‘749) signals a pivotal moment for schizophrenia treatment in Europe. This investigational four-weekly formulation aims to tackle one of the most persistent challenges in managing schizophrenia: medication adherence. Studies consistently show that non-compliance with oral antipsychotics is a significant driver of relapse and rehospitalization, imposing substantial burdens on patients and healthcare systems. By offering a long-acting injectable, this new olanzapine option could dramatically improve treatment continuity, leading to more stable symptom control and better long-term outcomes for patients.

Olanzapine is a well-established atypical antipsychotic, recognized for its efficacy in managing schizophrenia and bipolar disorder. However, its utility has been tempered by a known propensity for metabolic side effects, including weight gain, dyslipidemia, and an increased risk of diabetes. While the new formulation promises improved adherence, clinicians will need to carefully balance olanzapine's efficacy with its metabolic profile, particularly for patients with pre-existing metabolic concerns.

The introduction of TEV-‘749 will also reshape the competitive landscape of long-acting injectable antipsychotics in Europe. It will join existing options like risperidone, paliperidone, and aripiprazole LAIs, offering clinicians another choice in their efforts to individualize patient care. However, the olanzapine LAI carries a specific safety consideration: the risk of post-injection delirium/sedation syndrome (PDSS), which, though rare, necessitates a mandated 3-hour observation period after each injection. This requirement could introduce logistical complexities for healthcare providers, potentially impacting the ease of administration and overall resource utilization. Despite these considerations, the potential for a convenient, effective, and adherence-enhancing olanzapine LAI represents a significant step forward, offering a new avenue to improve the lives of individuals living with schizophrenia.